Recent advances in pathophysiology, diagnosis and management of hepatorenal syndrome: A review

Table 3 Results of studies using vasoconstrictor therapy in patients with hepatorenal syndrome with acute kidney injury

Ref.	Study design	Treatment	Alb	HRS reversal (%)	Mortality (%)
Uriz et al[110], 2000	Prospective	Terlipressin	Yes	77	Not defined
Halimi et al[111], 2002	Retrospective	Terlipressin	No	72	Not defined
Moreau et al[112], 2002	Retrospective	Terlipressin	Yes	58	Not defined
Ortega et al[75], 2002	Prospective	Terlipressin	Yes	77	Not defined
Duvoux et al[113], 2002	Prospective	NE	Yes	83	Not defined
Solanki et al[60], 2003	Randomized	Terlipressin vs placebo	Yes	42 vs 0	58 vs 100
Alessandria et al[64], 2007	Randomized	Terlipressin vs NE	Yes	83 vs 70	25 vs 20
Neri et al[65], 2008	Randomized	Terlipressin vs placebo	Yes	81 vs 19	27 vs 58
Sharma et al[66], 2008	Randomized	Terlipressin vs NE	Yes	50 vs 50	45 vs 45
Sanyal et al[67], 2008	Randomized	Terlipressin vs placebo	Yes	34 vs 13	57 vs 62
Martin-Llahi et al[68], 2008	Randomized	Terlipressin vs placebo	Yes	44 vs 9	74 vs 83
Singh et al[69], 2012	Randomized	Terlipressin vs NE	Yes	39 vs 43	70 vs 65
Cavallin et al[70], 2015	Randomized	Terlipressin vs MID plus OCT	Yes	70 vs 29	30 vs 32
Cavallin et al[71], 2016	Randomized	Terlipressin infusion vs terlipressin bolus	Yes	56 vs 46	59 vs 43
Boyer et al[72], 2016	Randomized	Terlipressin vs placebo	Yes	24 vs 15	33 vs 35
Wong et al[73], 2019	Randomized	Terlipressin vs placebo	Yes	29 vs 16	73 vs 71
Wong et al[81], 2021	Randomized	Terlipressin vs placebo	Yes	32 vs 16	51 vs 45

Alb: Albumin; HRS: Hepatorenal syndrome; HRS-AKI: Hepatorenal syndrome with acute kidney injury; MID: Midodrine; NE: Norepinephrine; OCT: Octreotide.